Serum IL-8 and IL-12 levels in breast cancer

Medical Oncology

Volumn 24, Issue 2, 2007, Pages 163-168

  Derin, Duygu ^a   Soydinc, Hilal Oguz ^a   Guney, Nese ^a   Tas, Faruk ^a   Camlica, Hakan ^a   Duranyildiz, Derya ^a   Yasasever, Vildan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Chemotherapy; IL 12; IL 8; Serum

Indexed keywords

ANTHRACYCLINE; INTERLEUKIN 12; INTERLEUKIN 8; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-8; MIDDLE AGED; PROGNOSIS;

EID: 36248984827     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02698035     Document Type: Article

References (25)

1. Suri C, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 182: 468-471.
2. Teicher BA, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 1-6.
3. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 2003; 48: 82-84.
4. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995; 13: 251-276.
5. Blanks RE, Patel PM, Selby PJ. Interleukin-12: a new clinical player in cytokine therapy. Br J Cancer 1995; 71: 655-659.
6. O'Hara RJ, et al. Advanced colorectal cancer is associated with impaired Interleukin 12 and enhanced Interleukin 10 production. Clin Cancer Res 1998; 4: 1943-1948.
7. Nakayama Y, et al. Serum levels of interleukin-12 in patients with gastrointestinal cancer. Anticancer Res 2000; 20: 635-640.
8. Merendino RA, et al. Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett 1999; 68: 355-358.
9. Voest EE, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
10. Cavallo F, et al. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin-12. Cancer Res 1999; 59: 414-421.
11. Strieter RM, et al. Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 1992; 141: 1279-1284.
12. Belperio JA, et al. CXC chemokines in angiogenesis. J Leukocyte Biol 2000; 68: 1-8.
13. Kunz M, et al. Anoxia-induced up-regulation of interleukin-8 in human malign melanoma. A potential mechanism for high tumor aggressiveness. Am J Pathol 1999; 155: 753-763.
14. Benoy IH, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004; 10: 7157-7162.
15. Pusztai L, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokines 2004; 25: 94-102.
16. De Larco JE, et al. A potential role for interleukin-8 in the metastatic phenotype of breast carcinoma cells. Am J Pathol 2001; 158: 639-646.
17. Yokoe T, Lino Y, Morishita Y. Trends of IL-6 and IL-8 levels in patients with recurrent breast cancer: preliminary report. Breast Cancer 2000; 7: 187-190.
18. Lissoni P, et al. Interleukin-12 in early or advanced cancer patients. Eur J Cancer 1997; 33: 1703-1705.
19. Zeimet AG, et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998; 16: 1861-1868.
20. Kovacs E. The serum levels of IL-12 and IL-16 in cancer patients: relation to the tumour stage and previous therapy. Biomed Pharmacother 2001; 55: 111-116.
21. Urosevic M, Dummer R. HLA-G and IL-10 expression in human cancer. Sem Cancer Biol 2003; 13: 337-342.
22. Lissoni P, et al. Physiopathology of IL-12 in early or advanced cancer patients and their variations with surgery and immunotherapy. J Biol Regul Homeost Agents 1998; 12: 38-41.
23. Miller LT, et al. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res 1998, 18: 77-81.
24. Okamoto M, et al. Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck patients. Anticancer Drugs 2000; 11: 165-173.
25. Uslu R, et al. Predictive value of serum interleukin-8 in ovarian cancer patients treated with paclitaxel-containing regimens. Int J Gynecol Cancer 2005; 15: 240-245.